Antibody responses after two doses of SARS-CoV-2 mRNA-1273 vaccine in an individual with history of COVID-19 re-infection.


Journal

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
ISSN: 1878-3511
Titre abrégé: Int J Infect Dis
Pays: Canada
ID NLM: 9610933

Informations de publication

Date de publication:
Jun 2022
Historique:
received: 24 02 2022
revised: 10 03 2022
accepted: 12 03 2022
pubmed: 21 3 2022
medline: 18 5 2022
entrez: 20 3 2022
Statut: ppublish

Résumé

We present a case of a 58-year-old Japanese man with a history of 2 previous COVID-19 infections, who received 2 doses of mRNA-1273 vaccine. We are not aware of any previous study regarding antibody tendency after 2 infections and 2 vaccinations. We evaluated his IgG titer of antispike protein and neutralizing activity from the first infection before and after 2 doses of vaccine. Both antispike IgG titer and neutralizing activity showed a tendency to decline almost 1 year after initial infection; they rapidly increased after the first vaccination, and they remained high after the second vaccination. Although this is a single case report, it seems to have generalizability because the findings are consistent with previous reports regarding single infections or 3 doses of vaccination. Our findings suggest that a single booster shot may provide sufficient protection and aid the understanding of immunologic responses of vaccination in patients with COVID-19 with history of re-infection.

Identifiants

pubmed: 35306204
pii: S1201-9712(22)00155-2
doi: 10.1016/j.ijid.2022.03.017
pmc: PMC8925083
pii:
doi:

Substances chimiques

Antibodies, Neutralizing 0
Antibodies, Viral 0
COVID-19 Vaccines 0
Immunoglobulin G 0
2019-nCoV Vaccine mRNA-1273 EPK39PL4R4

Types de publication

Case Reports

Langues

eng

Sous-ensembles de citation

IM

Pagination

18-20

Informations de copyright

Copyright © 2022 The Author(s). Published by Elsevier Ltd.. All rights reserved.

Références

Infect Genet Evol. 2021 Oct;94:105013
pubmed: 34352360
Sci Rep. 2021 Nov 24;11(1):22848
pubmed: 34819514
JCI Insight. 2021 May 10;6(9):
pubmed: 33822773
J Infect Chemother. 2021 Jul;27(7):1063-1067
pubmed: 33962861
Glob Health Med. 2020 Apr 30;2(2):107-111
pubmed: 33330786
Transfusion. 2021 Jul;61(7):1998-2007
pubmed: 34096059
Sci Rep. 2021 Mar 10;11(1):5563
pubmed: 33692457
N Engl J Med. 2021 Jun 10;384(23):2259-2261
pubmed: 33822494
Clin Transl Immunology. 2021 Jul 26;10(7):e1319
pubmed: 34336207
N Engl J Med. 2021 Oct 14;385(16):1474-1484
pubmed: 34320281
Clin Case Rep. 2021 Oct 15;9(10):e04936
pubmed: 34691457
N Engl J Med. 2021 Apr 8;384(14):1372-1374
pubmed: 33691060
Lancet. 2021 Mar 27;397(10280):1204-1212
pubmed: 33743221

Auteurs

Makoto Inada (M)

Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.

Masahiro Ishikane (M)

Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan. Electronic address: ishikanemasahiro@gmail.com.

Mari Terada (M)

Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan; Center for Clinical Science, National Center for Global Health and Medicine, Tokyo, Japan.

Akihiro Matsunaga (A)

Department of Intractable Diseases, Research Institute, National Center for Global Health and Medicine, Tokyo, Japan.

Kenji Maeda (K)

Department of Refractory Viral Infections, Research Institute, National Center for Global Health and Medicine, Tokyo, Japan.

Noriko Iwamoto (N)

Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.

Mugen Ujiie (M)

Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.

Satoshi Kutsuna (S)

Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan; Professor, Department of Infection Control, Graduate School of Medicine, Osaka University, Osaka, Japan.

Shinichiro Morioka (S)

Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.

Yukihito Ishizaka (Y)

Department of Intractable Diseases, Research Institute, National Center for Global Health and Medicine, Tokyo, Japan; Vice Director General, Research Institute, National Center for Global Health and Medicine, Tokyo, Japan.

Hiroaki Mitsuya (H)

Department of Refractory Viral Infections, Research Institute, National Center for Global Health and Medicine, Tokyo, Japan; Director General, Research Institute, National Center for Global Health and Medicine, Tokyo, Japan.

Norio Ohmagari (N)

Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH